There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amicus (FOLD) and Insys Therapeutics (INSY) with bullish sentiments.
Amicus (FOLD)
Cantor Fitzgerald analyst Elemer Piros maintained a Buy rating on Amicus yesterday and set a price target of $20. The company’s shares closed yesterday at $12.44.
Piros said:
“We rate Amicus Therapeutics Overweight. Amicus focuses on treatments for lysosomal storage disorders and rare diseases. We foresee Galafold as becoming the standard of care for Fabry disease patients with amenable mutations around the world. We think beyond this approval, Amicus has a robust pipeline.”
According to TipRanks.com, Piros has 0 stars on 0-5 star ranking scale with an average return of -3.5% and a 42.7% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.
Amicus has an analyst consensus of Strong Buy, with a price target consensus of $17.60.
See today’s analyst top recommended stocks >>
Insys Therapeutics (INSY)
Cantor Fitzgerald analyst Brandon Folkes maintained a Buy rating on Insys Therapeutics yesterday and set a price target of $9. The company’s shares closed yesterday at $6.30.
Folkes wrote:
“We believe 2019 will be a pivotal and transformational year for Insys. The company has two potential filings with its spray platform this year, along with two significant data readouts from the company’s cannabinoids platform. Additionally, with the DOJ settlement and the trial of past executives behind them, we believe 2019 could be the year in which investors are able to return to INSY stock and appreciate the value which could be unlocked from within the company’s spray and cannabinoids pipeline in 2019 and beyond.”
According to TipRanks.com, Folkes is a 3-star analyst with an average return of 3.5% and a 41.8% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Insys Therapeutics with a $10 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
